1. Scrip
  2. >>Therapy Areas

MyoKardia's Mavacamten 'Impressive' In Hypertrophic Cardiomyopathy

Launch Planning Underway For The Biotech's Lead Candidate

 
• By John Davis

MyoKardia is building up its organization to prepare for commercialization of mavacamten, a potential first-in-class agent for obstructive hypertrophic cardiomyopathy.  

Cardiomyopathy
• Source: Shutterstock

Updated results from the Phase III EXPLORER-HCM trial have continued to portray the clinical benefits of MyoKardia, Inc.’s mavacamten in symptomatic, obstructive hypertrophic cardiomyopathy (HCM). With a US new drug application expected to be submitted in the first quarter of 2021, the Brisbane, CA-based company has sketched out commercialization plans for its lead first-in-class therapeutic candidate. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 
• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

 
• By Alaric DeArment

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.